Key regulatory developments include FDA approval of a new generic medical abortion pill (mifepristone) and the addition of Jazz Pharmaceuticals and Roche’s lung cancer therapy combination some days ahead of anticipated PDUFA deadlines. Furthermore, BioCentury reports on ongoing discussions around PDUFA reauthorization involving FDA and industry leaders and notes CMS progress on Medicare Part D Most Favored Nation (MFN) pricing rules under review by the White House.